CytoReason vs Neoflow Technologies
CytoReason vs Neoflow Technologies, compared side by side on 11 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Neoflow Technologies on 47/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 47/100
- funding raised: $128M against $10.0M
Neoflow Technologies
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CytoReason | Neoflow Technologies |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Develops an endovascular solution for vasospasm treatment in aneurysmal subarachnoid hemorrhage. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Medical Device, MedTech, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Hardware |
| Founded | 2016 | 2022 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | CytoReason | Neoflow Technologies |
|---|---|---|
| Employees | 116 | Not published |
| Headcount growthLast 12 months | +13.7% | Not published |
| Total funding | $128M | $10.0M |
| Latest round | Series B | Seed |
| LinkedIn followers | 12,830 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Neoflow Technologies |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 47/100 |
| Traction | 60/100 | 11/100 |
| Team | 70/100 | Not published |
| Search visibility | 30/100 | Not published |
| Quality | 78/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | Not published |
| Domain ratingLink authority, 0-100 | 40/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Neoflow Technologies |
|---|---|---|
| Analytics | Segment | Not detected |
CytoReason vs Neoflow Technologies: common questions
Which is better, CytoReason or Neoflow Technologies?
On our 0-100 score CytoReason rates higher (68/100 against 47/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 11 data points above: read the rows that match what you are buying for.
How do CytoReason and Neoflow Technologies compare on the numbers?
CytoReason leads on our overall score (68/100 against 47/100), funding raised ($128M against $10.0M).
Read the full CytoReason review and pricing or the Neoflow Technologies review and pricing. You can also browse other CytoReason alternatives we track.